Adolescent, Caregiver, and Young Adult Perspectives of the Transition From Pediatric to Adult Care for Sickle Cell Disease: A Preliminary Evaluation of the Sickle Cell Disease Transition Program
23 juni 2014 bijgewerkt door: St. Jude Children's Research Hospital
Sickle cell disease (SCD) is a debilitating genetic disorder affecting 70,000-100,000 Americans. It is frequently associated with very serious medical complications. For children with SCD, successfully transitioning to adult care is a vital step in ensuring continuity of care, managing their disease, and improving their health outcomes. Transition programs have been created to facilitate the transition process. However, few studies have assessed transition readiness and whether transition program components meet the transition needs of patients and families.
The purpose of this study is to explore transitioning from pediatric care to adult care and to assess components of the SJCRH SCD Transition Program from three perspectives: adolescents with SCD, their caregivers, and young adults with SCD who have transitioned to adult care. Data collection methods will include focus groups, questionnaires, and checklists. Qualitative data analysis procedures will be used to examine the data.
Studie Overzicht
Gedetailleerde beschrijving
In this study, through the use of focus groups and questionnaires, we will identify perceptions of transition from pediatric to adult care, transition readiness, disease knowledge, and self-management skills, and assess components of the St. Jude Children's Research Hospital (SJCRH) Sickle Cell Disease Transition Program.
Participants will participate in focus groups to discuss transition and transition-related concepts and evaluate components of the transition program.
Additionally, participants will complete questionnaires about specific aspects of the transition program and about current disease knowledge and management skills.
Studietype
Observationeel
Inschrijving (Werkelijk)
55
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
Tennessee
-
Memphis, Tennessee, Verenigde Staten, 38105
- St. Jude Children's Research Hospital
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
12 jaar tot 30 jaar (Kind, Volwassen)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Allemaal
Bemonsteringsmethode
Niet-waarschijnlijkheidssteekproef
Studie Bevolking
- Adolescents with SCD (all genotypes) ages ≥ 12 years old and ≤ 18 years old and currently receiving services through the SJCRH Sickle Cell Disease Transition Program
- Caregiver of an adolescent with SCD who has resided with the adolescent for at least 2 years prior
- Young adults with SCD (all genotypes) ages ≥ 18 years old and ≤ 30 years old who have transitioned to adult care
Beschrijving
Inclusion Criteria:
- Adolescents with SCD (all genotypes) ages ≥ 12 years old and ≤ 18 years old and currently receiving services through the SJCRH Sickle Cell Disease Transition Program.
- Caregivers who have resided with the adolescent with SCD for at least 2 years prior.
- Young adults with SCD (all genotypes) ages ≥ 18 years old and ≤ 30 years old who have transitioned to adult care
Exclusion Criteria:
- Non-English speakers.
- Adolescents and young adults with sickle cell trait.
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: Cohort
- Tijdsperspectieven: Prospectief
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Adolescents
Adolescents with SCD (all genotypes) age 12 years old up to 18 years old and currently receiving services through the St. Jude Children's Research Hospital Sickle Cell Disease Transition Program.
|
In this study, through the use of focus groups and questionnaires, we will identify perceptions of transition from pediatric to adult care, transition readiness, disease knowledge, and self-management skills, and assess components of the St. Jude Children's Research Hospital (SJCRH) Sickle Cell Disease Transition Program.
Participants will participate in focus groups to discuss transition and transition-related concepts and evaluate components of the transition program.
Additionally, participants will complete questionnaires about specific aspects of the transition program and about current disease knowledge and management skills.
Andere namen:
|
|
Caregivers
Caregiver of an adolescent with SCD who has resided with the adolescent for at least two years prior.
|
In this study, through the use of focus groups and questionnaires, we will identify perceptions of transition from pediatric to adult care, transition readiness, disease knowledge, and self-management skills, and assess components of the St. Jude Children's Research Hospital (SJCRH) Sickle Cell Disease Transition Program.
Participants will participate in focus groups to discuss transition and transition-related concepts and evaluate components of the transition program.
Additionally, participants will complete questionnaires about specific aspects of the transition program and about current disease knowledge and management skills.
Andere namen:
|
|
Young Adults
Young adults with SCD (all genotypes) age equal to 18 years up to and equal to 30 years of age who have transitioned to adult care.
|
In this study, through the use of focus groups and questionnaires, we will identify perceptions of transition from pediatric to adult care, transition readiness, disease knowledge, and self-management skills, and assess components of the St. Jude Children's Research Hospital (SJCRH) Sickle Cell Disease Transition Program.
Participants will participate in focus groups to discuss transition and transition-related concepts and evaluate components of the transition program.
Additionally, participants will complete questionnaires about specific aspects of the transition program and about current disease knowledge and management skills.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Grounded theory qualitative analysis of data
Tijdsspanne: 1 day
|
First, data will be prepared for qualitative analysis.
Digital audio files from the focus groups will be transcribed verbatim and questionnaire data will be entered into an Excel data file.
Second, focus group data will be qualitatively analyzed using the constant comparative process.
A qualitative data analysis program, NVivo9 (Victoria, Australia) will be used to assist with this coding process.
|
1 day
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start
1 maart 2012
Primaire voltooiing (Werkelijk)
1 maart 2014
Studie voltooiing (Werkelijk)
1 maart 2014
Studieregistratiedata
Eerst ingediend
30 maart 2012
Eerst ingediend dat voldeed aan de QC-criteria
2 april 2012
Eerst geplaatst (Schatting)
3 april 2012
Updates van studierecords
Laatste update geplaatst (Schatting)
24 juni 2014
Laatste update ingediend die voldeed aan QC-criteria
23 juni 2014
Laatst geverifieerd
1 juni 2014
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- XPD12-025 TRANSCD
- U1EMC19331 (Ander subsidie-/financieringsnummer: Health Resources and Services Administration)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
product vervaardigd in en geëxporteerd uit de V.S.
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .